Coagulation factor II, thrombin

Overview

Coagulation factor II, thrombin is a central serine protease in the coagulation cascade and the active enzymatic form of prothrombin (coagulation factor II). It plays a pivotal role in hemostasis by converting fibrinogen to fibrin, promoting clot formation, and amplifying coagulation through activation of other clotting factors and platelets. Because of these functions, thrombin is both a key physiological mediator of blood clotting and an important therapeutic target in thrombosis and anticoagulation research.

Beyond its classical role in coagulation, thrombin is also implicated in inflammatory and fibrotic signaling. Recent biomedical studies have linked thrombin activity to disease processes such as sepsis, pulmonary fibrosis, and broader coagulation abnormalities. Its signaling effects can involve pathways such as PAR-1-mediated responses and interactions with growth factors including TGF-β1 and VEGF, making thrombin relevant not only to thrombosis but also to inflammation, tissue remodeling, and vascular pathology.

Focus of Latest Publications

Recent publications have continued to examine coagulation factor II, thrombin, as both a therapeutic target and a biomarker-linked component of coagulation biology. In a review of emerging anticoagulant strategies, thrombin was highlighted as one of the established direct oral anticoagulant targets, with the authors noting that current thrombin-directed therapies remain limited by bleeding risk and motivating interest in alternative anticoagulant and fibrinolytic approaches.

Several studies focused on thrombin within disease-associated coagulation and thrombotic pathways. In middle-aged adults, abdominal fat measures were evaluated alongside thrombin generation readouts, including endogenous thrombin potential and peak thrombin, to assess sex-specific prothrombotic changes associated with visceral adipose tissue, abdominal subcutaneous adipose tissue, and liver fat content. In a separate allergy study, network pharmacology and proteomics implicated the complement and coagulation cascades, including F2 (thrombin), as part of the mechanism by which active metabolites may influence bovine serum albumin-induced allergy.

Thrombin was also investigated in experimental disease models and in silico analyses. In paraquat-induced pulmonary fibrosis, targeting thrombin with hirudin was reported to alleviate fibrosis through the PAR-1-mediated TGF-β1 pathway. In ischemic stroke research, a systematic network pharmacology study of Curcumae Rhizoma identified F2 (thrombin) among core targets, and molecular docking suggested that alexandrin and hederagenin could bind thrombin with potent affinity. Although the in vivo validation in that study primarily supported COX-2-mediated neuroinflammation attenuation, the authors proposed thrombin as part of the predicted multitarget network relevant to neuroprotection.

Additional work has explored thrombin-related functional inhibition in broader serine protease contexts. Plant-derived serine protease inhibitor peptides from Zingiber officinale, Allium sativum, and Momordica charantia showed thrombolytic activity and enzyme inhibition in vitro, with docking suggesting interactions with serine protease targets, though thrombin itself was not directly isolated as the sole target in the abstract. Collectively, these recent publications position thrombin as a recurring node in anticoagulation, fibrosis, stroke, allergy-associated coagulation changes, and thrombolytic research.

Key Publications

NEWJun Neuroprotective efficacy of Curcumae Rhizoma against ischemic stroke via attenuation of COX-2-mediated neuroinflammation: a systematic study predicting thrombin inhibition and highlighting alexandrin and hederagenin. (Metabolic brain disease, 2026, PMID 42301551): "Network analysis identified 20 active compounds and 49 core targets, including F2 (thrombin) and PTGS2 (COX-2)."
May Abdominal Fat Measures Are Associated With Sex-Specific Prothrombotic Changes in Middle-Aged Adults. (Arteriosclerosis, thrombosis, and vascular biology, 2026, PMID 42131917): "plasma levels of factor (F) VIII, FIX, FXI, fibrinogen, and thrombin generation (endogenous thrombin potential and peak thrombin)"
May Plant-derived serine protease inhibitor peptides: in vitro antimicrobial and antiviral activities combined with in silico mechanistic insights. (Archives of microbiology, 2026, PMID 42126587): "Molecular docking suggested potential interactions between peptide motifs and serine protease targets, providing a basis for experimental evaluation."
Apr Novel and experimental anticoagulant strategies beyond current direct oral anticoagulants. (Journal of thrombosis and haemostasis : JTH, 2026, PMID 41485707): "Treatment of thrombotic diseases has been revolutionized by direct oral anticoagulants (DOACs) targeting thrombin and factor (F)Xa."
Apr Integrated multi-omics approaches and network pharmacology analysis to explore the diagnosis and regulatory role of active metabolites in allergy. (Journal of pharmaceutical and biomedical analysis, 2026, PMID 41385805): "...eight activated differential metabolites affect the complement and coagulation cascades pathway through the proteins F10, F2, and PLG in BSA-induced allergy."
May Targeting thrombin with hirudin alleviates paraquat-induced pulmonary fibrosis via the PAR-1-mediated TGF-β1 pathway. (Histology and histopathology, 2026, PMID 41085213): "Thrombin is important for promoting fibrosis development."